wbf943 wbf943
Gæsteforsker
Molecular and Translational Pharmacology
Blegdamsvej 3B
2200 København N.
Medlem af:
Alexander Hovard Sparre-Ulrich has a part-time position as assistant professor at the Department of Biomedical Sciences (BMI). He actively teaches within the field of basic pharmacology.
Alexander is co-founder and CEO of Antag Therapeutics that is based on years of collaborative research from the University of Copenhagen with the focus on novel treatments for dietary-related metabolic diseases.
BMI and Antag Therapeutics collaborates on a variety of research projects with the aim of generating new knowledge that can be used in the prevention and treatment of diseases.
ID: 33841862
Flest downloads
-
255
downloads
GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Udgivet -
12
downloads
Effects of endogenous GIP in patients with type 2 diabetes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Udgivet -
11
downloads
Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Udgivet